Results 11 to 20 of about 302,228 (315)

Recurrent Venous Thromboembolism: What Is the Risk and How to Prevent It

open access: yesScientifica, 2012
Venous thromboembolism (VTE) that includes deep vein thrombosis and/or pulmonary embolism is a frequent, severe, and potentially lethal disease. After a first episode, VTE has a strong tendency to recur.
Gualtiero Palareti
doaj   +1 more source

Platelet biomechanics, platelet bioenergetics, and applications to clinical practice and translational research

open access: yesPlatelets, 2018
The purpose of this review is to explore the relationship between platelet bioenergetics and biomechanics and how this relationship affects the clinical interpretation of platelet function devices. Recent experimental and technological advances highlight
Mitchell J. George   +6 more
doaj   +1 more source

The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia

open access: yesHaematologica, 2015
Standard treatment for Glanzmann thrombasthenia is platelet transfusion. Recombinant activated factor VII has been shown to be successful in patients with Glanzmann thrombasthenia with platelet antibodies or who are refractory to platelet transfusions ...
Giovanni Di Minno   +5 more
doaj   +1 more source

Bone marrow CD34+ molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia

open access: yesFrontiers in Oncology, 2023
BackgroundMinimal residual disease (MRD) monitoring is an important tool to optimally address post-transplant management of acute myeloid leukemia (AML) patients.MethodsWe retrospectively analyzed the impact of bone marrow CD34+ molecular chimerism and ...
Michele Malagola   +18 more
doaj   +1 more source

The International Prospective Glanzmann Thrombasthenia Registry: Pediatric Treatment and Outcomes

open access: yesTH Open, 2019
Background Standard treatment for Glanzmann thrombasthenia (GT), a severe inherited bleeding disorder, is platelet transfusion. Recombinant activated factor VII (rFVIIa) is reported to be effective in GT with platelet antibodies and/or refractoriness to ...
Rainer B. Zotz   +3 more
doaj   +1 more source

ACTION OF HIGH-DISPERSED SILICA ON BLOOD COAGULATION FACTORS ACTIVATION [PDF]

open access: yesBiotechnologia Acta, 2013
Using of high-dispersed silica based sorbents is a new and prospective method of bleeding arrest. Studies of high-dispersed silica haemostatic action during superficial wounds were promising for its surgery usage. However the mechanisms of haemostatic
T. M. Chernyshenko   +6 more
doaj   +1 more source

The Endocannabinoid System: A Potential Therapeutic Target for Coagulopathies

open access: yesMetabolites, 2022
Abnormal blood coagulation or coagulopathy is a common manifestation of many pathological conditions. It occurs when there is an imbalance between the activities of the coagulation system and the fibrinolytic system, leading to excessive or impaired ...
Wujood Khayat, Christian Lehmann
doaj   +1 more source

Padua Prediction Score and Hospital-Acquired Proximal and Isolated Distal Deep Vein Thrombosis in Symptomatic Patients

open access: yesHematology Reports
Background: Hospital-acquired deep vein thrombosis (DVT) is an important cause of morbidity and mortality. Objectives: The purpose of this study was to evaluate the prevalence of proximal lower limb DVT and isolated distal DVT (IDDVT) and their ...
Michelangelo Sartori   +5 more
doaj   +1 more source

Association between Blood Group and Change in Coagulation Factors in Plasma Preparations for Transfusion Purpose at Kisii Teaching and Referral Hospital

open access: yesAdvances in Hematology, 2023
Background. Blood component therapy helps in managing patients with reduced hematopoiesis, elevated peripheral destruction of cells, and generalized blood loss (bleeding).
Collince Odiwuor Ogolla   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy